In this episode of Denatured, as part of our series of the European life science investment ecosystem, you'll be hearing from Regina Hodits, managing director at Angelini Ventures and Sofia Ioannidou, VC partner at Andera Life Sciences. They examine Germany’s biotech and life sciences landscape, focusing on the scientific, infrastructure and policy shifts required to enable European companies to scale globally while remaining anchored in Europe.HostJennifer C. Smith-Parker, Director of Insights, BioSpaceGuestsRegina Hodits, Managing Director, Angelini VenturesSofia Ioannidou, VC Partner, Andera Life SciencesDisclaimer: The views expressed in this discussion by guests are their own and do not represent those of their organizations.
Podzilla Summary coming soon
Sign up to get notified when the full AI-powered summary is ready.
Free forever for up to 3 podcasts. No credit card required.
Listen to This Episode
More from BioSpace
Rethinking hair loss treatment
ASCO wins from RevMed, Akeso/Summit, more; plus more Lilly and more China; ADA on deck
France’s biotech ecosystem: science, capital and scale
Lilly wheels and deals, Moderna gets boost on hantavirus scare, ASCO excitement builds
Get summaries like this every morning.
Free AI-powered recaps of BioSpace and your other favorite podcasts, delivered to your inbox.
Free forever for up to 3 podcasts. No credit card required.